Abbreviations used in this paper: \[Ca^2+^\]~i~, intracellular Ca^2+^ concentration; CCD, charge-coupled device; KRB, Krebs-Ringer buffer; PTD, protein transduction domain; SNAP-25, synaptosome-associated protein of 25 kD; TIRF, total internal reflection fluorescence; TIRFM, TIRF microscopy; VAMP, vesicle-associated membrane protein; WT, wild-type.

Introduction
============

Glucose-stimulated insulin release displays a biphasic pattern in both in vitro and in vivo systems ([@bib5]; [@bib33]). This pattern consists of a rapidly initiated and transient first phase preceding a sustained second phase. The ability of glucose to evoke first-phase release is shared by other stimuli (such as high KCl stimulation), resulting in membrane depolarization followed by increased cytosolic Ca^2+^, whereas only fuel secretagogues are able to initiate second-phase insulin release ([@bib9]). Electrophysiological experiments in single β cells have shown that first-phase release reflects Ca^2+^-dependent exocytosis of primed granules in a readily releasable pool of granules, whereas second-phase release involves an ATP-dependent release of granules that may be located further from the release site in a reserve pool ([@bib33]; [@bib32]). These results suggest that the two phases of release subject insulin granules to nonsynonymous regulatory mechanisms.

Fundamental components of secretory machinery, such as SNARE, required for the docking and fusion of vesicles in neuronal cells ([@bib37]), are expressed in pancreatic β cells and play an important role in insulin exocytosis ([@bib19]; [@bib40]; [@bib20]). Although the function of SNAREs in docking and fusion during exocytosis is already established ([@bib13]; [@bib37]), the distinct role of SNAREs in the individual phases of insulin release remains unclear.

Interestingly, the expression of t-SNARE, syntaxin 1A/HPC-1 (Synt1A; [@bib2]; [@bib10]), and its cognate SNARE partners, synaptosome-associated protein of 25 kD (SNAP-25) and vesicle-associated membrane protein 2 (VAMP2), reportedly decreased in islets of the Goto-Kakizaki rat, an animal model for human type 2 diabetes ([@bib20]; [@bib8]; [@bib43]), and in type 2 diabetic patients ([@bib30]). Because type 2 diabetes is associated with disturbances in the release pattern manifested as the selective loss of first-phase release ([@bib38]; [@bib27]; [@bib3]), SNAREs may have a specialized role in phasic insulin exocytosis. In the present study, we used Synt1A^−/−^ mice and total internal reflection fluorescence (TIRF) imaging to investigate a potential role for Synt1A in first-phase insulin release. Synt1A^−/−^ pancreatic β cells displayed no fusion from previously docked granules in first-phase release, whereas fusion from newcomers, which are responsible for second-phase release, was still preserved. Thus, we propose a new model for biphasic insulin release wherein docking and fusion of insulin granules is Synt1A dependent during the first phase but Synt1A independent during the second phase.

Results
=======

Interaction between insulin granules and Synt1A during biphasic insulin release
-------------------------------------------------------------------------------

We initially analyzed the dynamic interaction between insulin granules and Synt1A in control mouse β cells using dual-color TIRF microscopy (TIRFM). Expression of GFP-tagged insulin allowed insulin granule observation, and Synt1A was detected by a TAT-conjugated Cy3-tagged mAb. Here, we chose not to use a conventional overexpression approach, such as Synt1A tagged with GFP or RFP, because overexpression of syntaxin disturbs the function of endogenous syntaxin molecules ([@bib19]). Therefore, to analyze the interaction between insulin granules and Synt1A clusters during biphasic insulin release, we labeled the endogenous Synt1A clusters with TAT antibody. As previously reported ([@bib24]), TAT-conjugated Cy3-labeled anti-Synt1A antibody was rapidly transduced into living β cells (unpublished data). We ensured that TAT-conjugated Cy3-labeled anti-Synt1A antibody specifically labeled endogenous Synt1A clusters in the plasma membrane. Cells treated with TAT-conjugated Cy3 anti-Synt1A mAb for 50 min were fixed and immunostained with anti-Synt1A pAb. As shown in Fig. S1 (available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>), there was overlapping of Synt1A clusters labeled with TAT-conjugated Cy3 anti-Synt1A mAb (red) and those stained with anti-Synt1A pAb (green). In addition, it should be noted that most endogenous Synt1A was labeled with TAT antibody.

Pancreatic β cells that expressed insulin-GFP (Fig. S1, green) and were treated with TAT-conjugated Cy3 anti-Synt1A antibody (red) were stimulated by 22 mM glucose. Dual-color TIRF images were obtained every 300 ms ([Fig. 1 A](#fig1){ref-type="fig"}). Approximately 75% of insulin granule fusion during the first phase (\<4 min after stimulation) involved previously docked rather than newcomer granules ([Fig. 1 B](#fig1){ref-type="fig"}). We observed that most fusion events involving previously docked granules occurred at the site of Synt1A clusters ([Fig. 1, B and C](#fig1){ref-type="fig"}), whereas fusion from newcomers occurred at sites distinct from the Synt1A clusters. There was no significant difference in the number of fusion events between control (see [Fig. 3 B](#fig3){ref-type="fig"}) and TAT-conjugated Cy3 anti-Synt1A mAb--treated β cells ([Fig. 1 A](#fig1){ref-type="fig"}): the total number of fusion events from previously docked granules in wild-type (WT) versus TAT-treated cells was 18.2 ± 1.8 versus 14.9 ± 3.1 in 0--4 min (P = NS; *n* \> 5 cells), suggesting that the introduction of TAT-conjugated Cy3 anti-Synt1A mAb into β cells does not affect insulin exocytosis. These results suggest that first-phase release heavily involves a Synt1A-based SNARE complex, whereas second-phase release is chiefly independent of a Synt1A-based SNARE complex.

![**Dual-color TIRFM of dynamic interaction between docking and fusing GFP-tagged insulin granules and Cy3-labeled Synt1A clusters in glucose-induced insulin release in control mouse β cells.** 2 d after β cells were infected with the vector expressing insulin-GFP (green), cells were treated with TAT-conjugated Cy3-labeled anti-Synt1A antibody (red) for 50 min. Images were recorded for GFP-tagged insulin granules (green) and Cy3-labeled Synt1A clusters (red) simultaneously (300-ms intervals). (A) Sites of insulin granule fusion events during first-phase release under 22 mM glucose stimulation (0--4 min after glucose stimulation). Solid boxes (1 × 1 μm) represent the sites of fusion events at Synt1A clusters. Dashed boxes indicate the sites of fusion events not at Synt1A clusters (Video 1, available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>). (B) Analysis of fusion events during first-phase release (*n* = 5 cells). The fused granules are divided into two categories, fusion from previously docked granules (red) and newcomers (green). Previously docked granule indicates that the morphologically previously docked granule is fused with the plasma membrane. Newcomer indicates that the granule approaches from the inside (being absent before stimulation), reaches the plasma membrane, and quickly fuses. As previously reported ([@bib25]), ∼75% of insulin granule fusion during the first phase was from previously docked granules, and the remaining was from newcomers. Most fusion from previously docked granules occurred at Synt1A clusters (78.1 ± 4.0% of all fusion from previously docked granules); fusion from newcomers occurred external to Synt1A clusters (85.0 ± 2.9% of all fusion from newcomers) during the first phase. Data are mean ± SEM. (C) Sequential images (1 × 1 μm, 300-ms intervals; A, box indicated by arrow) of fusion from previously docked granules (green) at the Synt1A cluster (red) during the first phase. (D) Sites of insulin granule fusion during second-phase insulin release (\>5 min after glucose stimulation; Video 2). Solid and dashed boxes are as described above. (E) Analysis of fusion events during second-phase release, with fusion occurring mostly from newcomers ([@bib25]), and at sites distinct from Synt1A clusters (86.1 ± 1.2% of all fusion from newcomers; *n* = 5 cells). Data are mean ± SEM. (F) Sequential images (1 × 1 μm, 300-ms intervals; D, box indicated by arrow) of fusion from newcomers (green) external to Synt1A clusters (red) during the second phase.](jcb1770695f01){#fig1}

Morphometric analysis of insulin granules in Synt1A^−/−^ mice
-------------------------------------------------------------

If Synt1A is essential for docking and fusing insulin granules specifically during the first phase, the deletion of Synt1A may cause reduction in first-phase but not second-phase insulin release. To examine this hypothesis, we used β cells from Synt1A^−/−^ mice ([@bib7]) as a context for analyzing docking and fusion of insulin granules by TIRFM. We first investigated Synt1A protein levels in Synt1A^−/−^ versus WT mouse pancreatic islets. Fig. S2 (available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>) shows the lack of Synt1A protein expression in Synt1A^−/−^ islets. Expression of Synt1B was not observed in either Synt1A^−/−^ or WT islets, in accord with the report that Synt1B is expressed at very low levels in control β cells ([@bib19]), although the brain abundantly expresses Synt1B ([@bib2]). We found no difference between WT and Synt1A^−/−^ islets in expression levels of other plasma membrane proteins, such as Synt3, Synt4, the other SNAREs, and related proteins SNAP-25, VAMP2, and Munc18. We then examined the pancreatic islets morphologically (Fig. S3). We found that paraffin-embedded pancreatic tissue sections showed insulin immunofluorescence patterns typical for β cells with no notable difference between the Synt1A^−/−^ and WT islets (Fig. S3, A and B). EM of pancreatic β cells also revealed that cell size, total number of granules per section, and mean granule diameter were similar between WT and Synt1A^−/−^ β cells (Fig. S3, C--F). Thus, Synt1A^−/−^ β cells displayed specific Synt1A protein depletion but were similar to WT cells in these other traits assayed.

Docking status of insulin granules in Synt1A^−/−^ β cells
---------------------------------------------------------

We examined the docking status of insulin granules in Synt1A^−/−^ β cells using TIRFM with immunostaining for insulin ([Fig. 2 A](#fig2){ref-type="fig"}). Because evanescent field illumination reaches a \<100-nm-thick layer immediately adjacent to the cover glass under our TIRF conditions, TIRFM illuminates only the plasma membrane with its associated organelles, such as synaptic vesicles ([@bib42]), secretory granules ([@bib31]), and glucose transporter 4 (GLUT4) vesicles ([@bib17]), where a cell adheres tightly to the cover glass. We interpret the individual fluorescent spots shown in the TIRF image in [Fig. 2 A](#fig2){ref-type="fig"} to be equivalent to morphologically docked granules (see Materials and methods). We rarely observed morphologically docked granules in Synt1A^−/−^ β cells (number of docked granules: 253.3 ± 10.2 vs. 12.3 ± 2.2 granules per 200 μm^2^ in WT and Synt1A^−/−^ β cells, respectively; *n* = 12 cells; P \< 0.0001). Plasma membrane staining with a lipophilic dye ensured that the Synt1A^−/−^ β cells adhered tightly to the cover glass (unpublished data).

![**Synt1A deficiency impairs docking of insulin granules to the plasma membrane in pancreatic β cells.** (A) TIRFM of insulin granules morphologically docked to the plasma membrane. (left) Typical TIRF images of docked insulin granules in WT or Synt1A^−/−^ β cells. The surrounding lines represent the outline of cells that attached to the cover glass. Bar, 5 μm. Pancreatic β cells were prepared from WT and Synt1A^−/−^ mice, fixed, and immunostained for insulin. (right) Number of insulin granules morphologically docked to the plasma membrane. Individual fluorescent spots shown in TIRF images were manually counted per 200 μm^2^; *n* = 15 cells. (B) Electron micrograph of β cell sections. (top) Typical EM images of the plasma membrane area facing the blood capillary (C) of WT and Synt1A^−/−^ β cells (B). Bar, 500 nm. (bottom) Number of morphologically docked insulin granules per 10 μm of plasma membrane. Granules at their shortest distance of \<10 nm from the plasma membrane were qualified as morphologically docked granules (red arrowheads). Results are provided as the mean ± SEM.](jcb1770695f02){#fig2}

To confirm the TIRFM data, we used EM to examine insulin granules that were morphologically docked to the plasma membrane. Using EM, granules at their shortest distance of \<10 nm from the plasma membrane qualified as morphologically docked granules ([@bib31]; [Fig. 2 B](#fig2){ref-type="fig"}). The number of morphologically docked granules observed by EM was significantly reduced in Synt1A^−/−^ β cells (9.6 ± 1.5 vs. 0.8 ± 0.2 granules per 10 μm of plasma membrane in WT and Synt1A^−/−^ cells, respectively; *n* = 12 cells; P \< 0.0001). Along with the results of the morphometric analysis, these data suggest that Synt1A deficiency specifically impairs the docking of insulin granules to the plasma membrane.

Effects of Synt1A ablation on insulin exocytosis
------------------------------------------------

We explored the effects of Synt1A deficiency on the dynamic motion of single insulin granules. In agreement with what has been reported for rat β cells ([@bib25]), we found that in WT mouse β cells, fusion of insulin granules with the plasma membrane during first-phase release mainly involved previously docked granules ([Fig. 3, A and B](#fig3){ref-type="fig"}; and Video 3, available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>). In contrast, because Synt1A^−/−^ β cells have fewer docked granules, TIRF analysis in these cells showed that the fusion from previously docked granules was severely abolished ([Fig. 3, C and D](#fig3){ref-type="fig"}; and Video 4). Despite an appreciable number of fusion events from previously docked granules in WT β cells, there was no fusion from previously docked granules in Synt1A^−/−^ β cells (18.2 ± 1.8 vs.0 in 0--4 min, WT vs. Synt1A^−/−^; [Fig. 3, B and D](#fig3){ref-type="fig"}). However, some fusion from newcomer granules was observed during the first phase even in Synt1A^−/−^ β cells. During second-phase release (\>4 min), there was no significant difference in the total number of newcomer fusion events between WT and Synt1A^−/−^ β cells (WT, 43.1 ± 5.0, and Synt1A^−/−^, 49.8 ± 3.7, during 4--17 min; P = NS; *n* = 10 cells; [Fig. 3, B and D](#fig3){ref-type="fig"}). ELISA data evaluating endogenous insulin release from perfused WT and Synt1A^−/−^ β cells ([Fig. 3 E](#fig3){ref-type="fig"}) were compatible with the TIRFM data. The small peak of first-phase release from Synt1A^−/−^ β cells shown in perfusion analysis is inferred to be composed of fusion from newcomers. Both the amplitude and time course of the glucose-induced rise in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) measured using Fura-2 were similar between WT and Synt1A^−/−^ β cells ([Fig. 3 F](#fig3){ref-type="fig"}), suggesting that glucose metabolism and ATP production were normally processed in Synt1A^−/−^ β cells and that Synt1A does not affect the activity of the [l]{.smallcaps}-type Ca^2+^ channels. This disagrees with the results of other groups ([@bib41]; [@bib14]; [@bib15]), but the reason for the discrepancy is unknown.

![**Effects of Synt1A deficiency on glucose-induced biphasic insulin release.** (A) TIRFM of single insulin granule motion in WT β cells under 22 mM high glucose stimulation (Video 3, available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>). Red and green boxes indicate that the granules to be fused with the plasma membrane originated from previously docked (red) or newcomer (green) granules. Sequential images (1 μm × 1 μm; 300-ms intervals) of docking and fusion from the previously docked granules (red box) and the newcomers (green box) are presented. (B) Histogram of the number of fusion events (per 200 μm^2^) in WT β cells at 60-s intervals after stimulation (*n* =10 cells). The red column shows fusion from previously docked granules, and the green column shows fusion from newcomers. During the first phase, fusion occurred mostly from previously docked granules. The fusing granules during the second phase originated mostly from newcomers. (C) TIRFM during glucose stimulation in Synt1A^−/−^ β cells (Video 4) and sequential images of a newcomer granule docking and fusing (green box) under glucose stimulation. (D) Histogram of the number of fusion events (per 200 μm^2^) in the Synt1A^−/−^ cells at 60-s intervals after stimulation (*n* =10 cells). (E) Glucose-induced insulin release from perfused WT and Synt1A^−/−^ β cells stimulated with 22 mM glucose. The cells in the cell chamber (∼5 × 10^5^ cells per chamber) were perfused with KRB (0.5 ml/min) at 37°C, and the perfusate was analyzed for insulin by ELISA. (F) 22 mM glucose-induced changes in \[Ca^2+^\]~i~ in WT and Synt1A^−/−^ β cells. Changes in \[Ca^2+^\]~i~ were measured by 2 μM Fura-2 AM. Time 0 indicates when the high glucose was added. The fluorescence ratio (340/360) at time 0 was taken as 1. Results are provided as the mean ± SEM.](jcb1770695f03){#fig3}

Restoration of Synt1A expression in β cells of Synt1A^−/−^ mice
---------------------------------------------------------------

We performed rescue experiments to confirm Synt1A function in the docking and fusing of granules during first-phase release. We restored Synt1A protein expression to Synt1A^−/−^ β cells by infecting them with an adenovirus encoding Synt1A, Adex1CA Synt1A (Ax-Synt1A; [Fig. 4 A](#fig4){ref-type="fig"}). The number of Synt1A clusters was considerably restored, although to still subnormal levels (270.8 ± 13.0 vs. 212.4 ± 15.7, WT vs. Ax-Synt1A--infected Synt1A^−/−^ cells; P \< 0.05). In accordance with restored Synt1A cluster levels, the number of docked insulin granules in Ax-Synt1A--infected Synt1A^−/−^ cells was restored (261.1 ± 13.6 vs. 230.0 ± 12.0, WT vs. Ax-Synt1A--infected Synt1A^−/−^ cells; P = NS). Infection of Adex1CA Synt1A did not alter the number of SNAP25 clusters ([Fig. 4 B](#fig4){ref-type="fig"}) that interact with Synt1 clusters ([@bib16]). We then performed TIRFM analysis of the docking and fusion of insulin granules stimulated by 22 mM glucose in Ax-Synt1A--infected Synt1A^−/−^ β cells. This analysis showed a substantial increase in fusion events from previously docked granules ([Fig. 4 D](#fig4){ref-type="fig"} and Video 5, available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>). The total number of fusion events from previously docked granules during the first phase in Ax-Synt1A--infected Synt1A^−/−^ β cells was restored (18.2 ± 1.8 vs. 12.7 ± 3.3 in 0--4 min, WT vs. Ax-Synt1A-- infected Synt1A^−/−^ cells; P = NS). Synt1A restoration did not affect fusion events from newcomers during the second phase. In addition, we examined the interaction between insulin granules and Synt1A clusters labeled with TAT-conjugated Cy3 anti-Synt1A mAb in Ax-Synt1A--infected Synt1A^−/−^ cells. Dual-color TIRFM showed that previously docked granules fused at the site of the Synt1A clusters during the first phase; during the second phase, newcomer granules fused external to the Synt1A clusters ([Fig. 4, E and F](#fig4){ref-type="fig"}). This was also observed in WT β cells. These data support a model where Synt1A clusters are required for previously docked granules to dock and fuse during the first phase but dispensable for newcomers to dock and fuse during the second phase.

![**Rescue of the number of docked insulin granules and fusion events by restoring Synt1A clusters to normal levels in Synt1A^−/−^ β cells.** (A--C) TIRF images and the quantitation of Synt1A clusters (A), SNAP-25 clusters (B), and docked insulin granules (C) on the plasma membrane in WT or Synt1A^−/−^ β cells. Synt1A^−/−^ cells were infected with empty virus Adex1w (Ax-Cont) or with Adex1CA Synt1A (Ax-Synt1A). Cells were fixed and immunostained for Synt1A (A), SNAP-25 (B), and insulin (C). (top) Typical TIRF images. Surrounding lines represent the outline of cells attached to the cover glass. Bars, 5 μm. (bottom) Number of Synt1A (A) and SNAP-25 (B) clusters and docked insulin granules (C) on the plasma membrane. Individual fluorescent spots in TIRF images were manually counted per 200 μm^2^. Data are mean ± SEM (\*, P \< 0.05; \*\*, P \< 0.0001; *n* = 15 cells). (D) Rescue of fusion events in Synt1A^−/−^ β cells. Synt1A^−/−^ cells were infected with Adex1CA insulin GFP and then Ax-Cont or Ax-Synt1A. The histogram shows the number of fusion events (per 200 μm^2^) at 60-s intervals after high glucose stimulation. A marked increase in fusion events from previously docked granules was observed in the Synt1A^−/−^ cells infected with Ax-Synt1A relative to Ax-Cont--infected cells. (E) Dual-color TIRFM of docking and fusing GFP-tagged insulin granules (green) and Synt1A clusters labeled with TAT-conjugated Cy3-labeled anti-Synt1A antibody (red) in glucose-induced release from Ax-Synt1A--infected Synt1A^−/−^ cells. Most fusion from previously docked granules occurred at Synt1A clusters (76% of all fusion from previously docked granules); fusion from newcomers occurred external to Synt1A clusters (81% of all fusion from newcomers) during the first phase. Data are mean ± SEM (*n* = 5 cells). Solid boxes (1 μm × 1 μm) represent the sites of fusion events at the Synt1A clusters. Dashed boxes indicate the sites of fusion events external to the Synt1A clusters. (F) Sites of insulin granule fusion during second-phase insulin release (\>4 min after glucose stimulation). Fusion events during second-phase release occurred mostly from newcomers and at sites distinct from Synt1A clusters (82% of all fusion from newcomers; *n* = 5 cells). Data are mean ± SEM. Solid and dashed boxes are as described above.](jcb1770695f04){#fig4}

Other plasma membrane syntaxins assayed are not involved in second-phase release
--------------------------------------------------------------------------------

As shown in [Fig. 3 D](#fig3){ref-type="fig"}, the fusion of newcomers during the second phase was well preserved in the absence of Synt1A. Yet the question remained of whether other syntaxin isoforms might be functioning in second-phase release, as pancreatic β cells do express detectable levels of plasma membrane--localized syntaxin isoforms, such as Synt3 and -4 ([@bib11]; [@bib40]). To investigate whether these membrane syntaxins Synt3 and -4 are involved in the second phase, we used TAT fusion proteins that encode the Synt3-H3 (TAT-Synt3-H3) and Synt4-H3 (TAT-Synt4-H3) domains. We previously reported that the recombinant Synt1A SNARE motif (H3 domain) fused to TAT (TAT-Synt1A-H3) rapidly transduced into MIN6 β cells, inhibiting insulin release ([@bib23]). Because the syntaxin H3 domain contributes to one of the four α-helical bundles in the SNARE core complex ([@bib12]), a large molar excess of the Synt1A-H3 domain fused to TAT interrupted the formation of functional SNARE complexes ([@bib23]), as previously reported in other systems ([@bib44]; [@bib21]). We therefore used TAT-H3 of each syntaxin isoform to perform dominant-negative type experiments.

We first produced TAT fusion proteins encoding the Synt3-H3 (TAT-Synt3-H3) and Synt4-H3 (TAT-Synt4-H3) domains. In addition, we produced TAT fusion proteins that encoded the Synt1A-H3 (TAT-Synt1A-H3) and Synt1B-H3 (TAT-Synt1B-H3) domains. A non--coiled-coil domain of ELKS, which has no effect on insulin exocytosis, composed the peptide fusion in our TAT-Control ([@bib26]). As shown in [Fig. 5](#fig5){ref-type="fig"} (C and D), the transduction of TAT-Synt3-H3 and TAT-Synt4-H3 into WT β cells reduced the number of fusion events from previously docked granules during the first phase to ∼58 and ∼59% that of control levels, respectively. Second-phase release, which consisted mostly of newcomers, was unaffected by the Synt3-H3 and Synt4-H3 constructs expressed. TAT-Control treatment had no effect on either phase ([Fig. 5 A](#fig5){ref-type="fig"}). However, TAT-Synt1A-H3 treatment strongly reduced the total number of fusion events from previously docked granules during the first phase to ∼23% that of control levels, while showing no effect on second-phase release ([Fig. 5 B](#fig5){ref-type="fig"}). These data are consistent with our results from Synt1A^−/−^ β cells. Synt1B does not express in β cells, but TAT-Synt1B-H3 treatment showed results similar to those in the TAT-Synt1A-H3 treatment, reducing the total number of fusion events from previously docked granules during the first phase to ∼28% that of control levels ([Fig. 5 E](#fig5){ref-type="fig"}). This may be a reflection of a higher homology of Synt1B-H3 to Synt1A-H3. Overall, these findings suggest that these other syntaxin family members are not involved in second-phase release.

![**TIRFM of fusion of GFP-tagged insulin granules in biphasic insulin release from WT β cells treated with TAT-syntaxin-H3.** WT cells expressing GFP-tagged insulin were treated with or without 70 mg/ml of TAT-Cont (A), TAT-Synt1A-H3 (B), TAT-Synt3-H3 (C), TAT-Synt4-H3 (D), or TAT-Synt1B-H3 (E) fusion protein for 50 min, and TIRF images were acquired every 300 ms by 22 mM glucose stimulation. The histogram shows the number of fusion events (*n* = 10 cells each) at 1-min intervals after high glucose stimulation in the TAT fusion protein--treated cells. The red column shows the fusion from previously docked granules, and the green column shows fusion from newcomers. Data are mean ± SEM.](jcb1770695f05){#fig5}

Synt1A ablation results in impaired glucose tolerance
-----------------------------------------------------

Because Synt1A^−/−^ β cells exhibit reduced first-phase insulin release, these mice would be expected to develop diabetes. The Goto-Kakizaki rat model for human type 2 diabetes is known to be defective in first-phase insulin release and displays hyperglycemia ([@bib29]). In contrast, we found that Synt1A^−/−^ mice did not show any significant hyperglycemia; fasting blood glucose levels of Synt1A^−/−^ mice were not different from those of WT mice (Synt1A^−/−^, 63.9 ± 4.3 mg/dl \[*n* = 7\], vs. WT, 65.1 ± 3.3 mg/dl \[*n* = 11\]; P = NS). However, the oral glucose tolerance test did show impaired glucose tolerance in Synt1A^−/−^ mice ([Fig. 6 A](#fig6){ref-type="fig"}). 30 min after challenge, blood glucose levels in Synt1A^−/−^ mice were significantly higher than in WT mice (Synt1A^−/−^, 385.0 ± 14.1 mg/dl \[*n* = 7\], vs. WT, 286.3 ± 10.4 mg/dl \[*n* = 11\]; P \< 0.0001). In agreement with these data, we found serum insulin levels to be lower in Synt1A^−/−^ than in WT mice at 30 min after challenge ([Fig. 6 B](#fig6){ref-type="fig"}). Thus, Synt1A^−/−^ mice displayed an impaired glucose tolerance but not marked hyperglycemia.

![**Glucose tolerance test in WT and Synt1A^−/−^ mice.** (A) Oral glucose tolerance was tested in WT (*n* = 11) and Synt1A^−/−^ (*n* = 7) mice. Blood glucose levels were measured at the indicated times after glucose challenge at 2 g glucose/kg body weight (*n* = 6 each; \*, P \< 0.005; \*\*, P \< 0.0001). (B) Plasma insulin levels were measured in WT and Synt1A^−/−^ mice during the oral glucose tolerance test at the indicated times. Results are provided as the mean ± SEM.](jcb1770695f06){#fig6}

Discussion
==========

Our dual-color TIRFM approach has shown that during first- phase release insulin granules fuse at the site of Synt1A clusters, but during second-phase release the granules fuse external to Synt1A clusters. We previously found that granules fusing during the first phase originated mostly from morphologically previously docked granules, whereas granules fusing during the second phase arose from newcomers that were originally stored intracellularly ([@bib25]). We also reported that previously docked insulin granules were colocalized with Synt1A clusters in the plasma membrane of MIN6 β cells ([@bib24]). Collectively, these findings suggested that Synt1A is probably essential for docking and fusing insulin granules during the first phase; however, no direct evidence existed to verify this. Recently, it was reported that other isoforms of the syntaxin family might be associated with biphasic insulin release ([@bib34]; [@bib36]). We therefore used Synt1A^−/−^ mice to directly address how Synt1A functions in granule docking and fusing in biphasic insulin exocytosis.

First, we examined the docking status of insulin granules in Synt1A^−/−^ β cells. TIRFM and EM analysis in Synt1A^−/−^ β cells documented a marked reduction of the number of granules docked onto the plasma membrane. Because granules fused during the first phase originated from docked granules, as expected, TIRFM revealed that there was no fusion from docked granules during the first phase in knockout cells. However, fusion from newcomers was still preserved in Synt1A^−/−^ β cells under glucose stimulation. Consistent with these data, perfusion analysis of Synt1A^−/−^ β cells showed a marked reduction in first-phase insulin release but no change in second-phase release. Furthermore, restoration of Synt1A to subnormal levels via the adenoviral vector in Synt1A^−/−^ β cells restored the insulin granules docked onto the plasma membrane, accompanied by an appreciable number of fusion events from these granules. Thus, our data provide direct evidence that Synt1A is essential for docking and fusion of insulin granules during first-phase release. The docking status of synaptic vesicles in the brain hippocampus showed no difference between WT and Synt1A^−/−^ mice ([@bib7]). The reason for this discrepancy between brain and pancreatic β cells is unknown, but it may be due to the expression of Synt1B, which is highly homologous to Synt1A and is abundant in brain cells ([@bib2]) but not in pancreatic β cells ([@bib19]). Although the function of Synt1B may not be equal to that of Synt1A in pancreatic β cells ([@bib19]), the brain may have either a tremendous safety network or a different system from pancreatic β cells that permits Synt1B or other homologues to compensate for the lack of Synt1A in brain tissue.

Although our data specify a requirement for Synt1A during first-phase release, we still do not know whether other isoforms of the syntaxin family participate in the first phase. WT β cells transduced with TAT-Synt3-H3 and TAT-Synt4-H3, which function in a dominant-negative manner to the corresponding syntaxin isoforms, showed reduction to some extent in the fusion events from previously docked granules during the first phase ([Fig. 5](#fig5){ref-type="fig"}). Yet, as no docked insulin granules were seen on the plasma membrane in Synt1A^−/−^ mice, it is difficult to conclude that both Synt3 and -4 are associated with first-phase exocytosis. Rather, we assume that the reduction of fusion events during the first phase by TAT-Synt3-H3 and TAT-Synt4-H3 treatment may reflect the homology of their amino acid sequence to Synt1A-H3. Nevertheless, it remains to be empirically determined if, and how, the other plasma membrane syntaxins contribute to the first phase.

Fusion from newcomer granules was not altered at all regardless of Synt1A deletion, indicating that this type of fusion may occur via some mechanism other than the Synt1A-based SNARE complex. Indeed, granule behavior between the first and second phases of release is quite different. As previously reported, upon reaching the plasma membrane, newcomers fused immediately (\<50 ms), whereas granules previously docked on the plasma membrane stayed at the same place for a relatively long time ([@bib25]). To examine the possibility that other syntaxin isoforms are involved in second-phase exocytosis, we performed dominant-negative type experiments with TAT-Synt3-H3 and TAT-Synt4-H3 and demonstrated that there was no correlation between syntaxins and second-phase exocytosis. In agreement with our data, [@bib36] noted only a slight decrease in second-phase insulin release in Synt4^+/−^ mice. Thus, it is plausible that the first phase is Synt1A dependent but the second phase is Synt1A independent, as depicted in the [Fig. 7](#fig7){ref-type="fig"}. A similar phenomenon exists in neurotransmitter release, where neural t-SNARE SNAP-25 is essential for evoked neurotransmitter release but nonessential for nonevoked release ([@bib39]). Furthermore, fusion via neural v-SNARE VAMP2 in evoked neurotransmitter release differs from spontaneous neurotransmitter release ([@bib35]). Of course, we do not know whether an evoked or spontaneous release in neurons is compatible with the first and second phases of insulin release in pancreatic β cells, respectively, but there must be some unknown mechanism (other than the SNARE-mediated docking and fusion reactions) in different cell types. Further studies will be required to identify the specific molecules involved in newcomer fusion.

![**Schematic drawing of the role of Synt1A in biphasic insulin release.** During first-phase insulin release, granules dock to Synt1A clusters and fuse at the site of Synt1A clusters. During second-phase release, granules move to the plasma membrane from the intracellular store and then fuse with the plasma membrane without any interaction with Synt1A clusters.](jcb1770695f07){#fig7}

In the present study, we also examined the in vivo effect of Synt1A ablation followed by reduced first-phase insulin release on glucose homeostasis. The lack of first-phase insulin release is a main manifestation of type 2 diabetes ([@bib38]; [@bib27]; [@bib3]). This phenomenon is quite similar to the insulin release pattern observed in the perfusion of Synt1A^−/−^ β cells. Therefore, we expected Synt1A^−/−^ mice to become diabetic. The in vivo studies showed that Synt1A^−/−^ mice had impaired oral glucose tolerance and decreased serum insulin levels; however, there was no marked hyperglycemia. Thus, factors other than Synt1A depletion may be required to drive hyperglycemia. Williams-Beuren syndrome ([@bib18]) is an interesting clinical case when considering the role of Synt1A in diabetes pathogenesis. This syndrome is a multisystem developmental disorder caused by the hemizygous deletion of a 1.5-million-bp region of chromosome 7q11.23 ([@bib6]), which includes the Synt1A gene ([@bib28]). Only some Williams-Beuren syndrome patients exhibit impaired glucose tolerance ([@bib4]). This may be due to the hemizygous deletion; however, it is also postulated that deletion of only Synt1A is not enough to cause abnormal glucose homeostasis.

In summary, the present study has provided the first documentation that first-phase insulin release is Synt1A dependent, but second-phase release is Synt1A independent, highlighting that the two phases differ not only spatially but also mechanistically. In a physiological context, our data supporting glucose intolerance in Synt1A^−/−^ mice in vivo encourage therapeutic consideration of the significance of Synt1A in first-phase insulin release.

Materials and methods
=====================

Generation of Synt1A^−/−^ mice
------------------------------

We generated Synt1A^−/−^ mice as previously described ([@bib7]). The genotyping of mice was performed by PCR. Mice were backcrossed with strain C57BL/6 over at least five generations and were used at the age of 10--14 wk. Animal experiments were approved by the Kyorin University Animal Care Committee.

Cells
-----

Pancreatic islets of Langerhans were isolated from male WT and Synt1A^−/−^ mice by collagenase digestion as described previously ([@bib25]). Isolated islets were dispersed in calcium-free Krebs-Ringer buffer (KRB) containing 1 mM EGTA and cultured on fibronectin-coated (KOKEN Co.), high refractive index cover glass (Olympus) in RPMI 1640 medium (Invitrogen) supplemented with 10% FBS (Invitrogen), 200 U/ml penicillin, and 200 μg/ml streptomycin at 37°C in an atmosphere of 5% CO~2~. To label the insulin secretory granules, pancreatic β cells were infected with recombinant adenovirus Adex1CA insulin-GFP as described previously ([@bib25]). For Synt1A rescue experiments, cells were infected with Adex1CA Synt1A ([@bib20]) before being infected with Adex1CA insulin-GFP. Experiments were performed 2 d after the final infection.

Immunoblotting
--------------

Proteins were extracted from mouse whole brain or mouse pancreatic islets and immunoblotted as previously described ([@bib26]). Anti-Synt1A mAb and anti-Synt1B pAb were obtained also as previously described ([@bib7]). Antibodies against Synt3 (Synaptic Systems GmbH), Synt4 (BD Biosciences), SNAP-25 (Wako), VAMP2 (Wako), and Munc18 (BD Biosciences) were purchased from commercial sources.

Immunostaining
--------------

WT and Synt1A^−/−^ β cells cultured on high refractive index glass were fixed and made permeable with 2% paraformaldehyde/0.1% Triton X-100 and were processed for immunohistochemistry as described previously ([@bib25]). Cells were labeled with anti-insulin mAb (Sigma-Aldrich), Synt1A, and SNAP-25 and processed with goat anti--mouse IgG conjugated to Alexa Fluor 488 (Invitrogen; [@bib25]). Immunofluorescence was detected by TIRFM. This procedure allowed us to evaluate the number of docked insulin granules and clusters of Synt1A and SNAP-25.

EM
--

EM was performed by conventional methods as previously described ([@bib1]). Tissues were fixed in phosphate-buffered 2.5% glutaraldehyde, pH 7.4, postosmicated, dehydrated with graded alcohols, and embedded in Epon 812. After staining with uranyl acetate and lead citrate, ultrathin sections were examined with a transmission electron microscope (TEM-1010C; JEOL). In EM, granules at their shortest distance of \<10 nm from the plasma membrane were qualified as morphologically docked granules ([@bib31]).

Morphometric analysis of islets
-------------------------------

For the analysis of islet size and β cell mass, paraffin-embedded pancreas sections (10 μm) were labeled with anti-insulin antibody and detected by an avidin-biotin-peroxidase technique (Vector Laboratories). Sections were collected at 500-μm intervals from tissue blocks, and all islets in the sections were analyzed as islet area over total pancreatic area. Images were acquired with a microscope (IX70; Olympus) that was equipped with a charge-coupled device (CCD) camera and analyzed with MetaMorph software (Universal Imaging Corp.).

TAT-conjugated antibody
-----------------------

TAT-conjugated Cy3-labeled anti-Synt1A antibody was prepared as described elsewhere ([@bib24]). In brief, anti-Synt1A mAb was labeled with Cy3 by use of a Fluoro Link antibody Cy3 labeling kit (GE Healthcare), according to the manufacturer\'s instructions. The Cy3-labeled antibody was dialyzed against 0.1 M borate buffer and was incubated with a fivefold molar excess of a cross-linker, sulfosuccinimidyl 6-(3′-\[2-pyridyldithio\]-propionamido) hexanoate (Pierce Chemical Co.) for 3 h at room temperature. The conjugated antibody was separated from the free cross-linker by gel filtration eluted with 5 mM Hanks\' Hepes buffer, pH 7.2. A 10-fold molar excess of TAT protein transduction domain (PTD) peptide (GYGRKKRRQRRRGGGC) was added to the conjugated antibody, and the mixture was incubated overnight at 4°C. The TAT-conjugated antibody was separated from the free TAT PTD peptide by gel filtration eluted with 5 mM Hanks\' Hepes buffer. On the day of TIRFM experiments, Adex1CA insulin-GFP--infected cells were treated with ∼120 μg/ml TAT-conjugated Cy3-labeled anti-Synt1A mAb for 50 min as described previously ([@bib24]).

TAT fusion proteins
-------------------

To produce constructs in which the TAT PTD peptide is located at the N terminus of Synt1A-H3 (aa 202--265), Synt1B-H3 (aa 201--264), Synt3-H3 (aa 201--264), Synt4-H3 (aa 210--273), or control peptides (non--coiled-coil domain of ELKS; aa 324--403; [@bib26]), the coding region that corresponds to rat Synt1A-H3, Synt1B-H3, Synt3-H3, Synt4-H3, or control peptides was amplified by PCR by using oligonucleotide primers, including the nucleotide sequence against the TAT PTD peptide (YGRKKRRQRRR) in each sense primer, as described previously ([@bib23]). PCR products were subcloned into a pPROEX HTa bacterial expression vector (Invitrogen) with an additional His~6~ tag at the N terminus. The resulting products were confirmed by an automated DNA sequencer (GE Healthcare). TAT fusion proteins in the pPROEX HTa vector were expressed in a DH5α *Escherichia coli* strain by induction with isopropyl-b-[d]{.smallcaps}-thiogalactopyranoside for 5 h at 37°C. The recombinant proteins were extracted with 8 M urea in 50 mM Tris and 100 mM KCl, pH 8.0. Urea extracts were incubated with Ni-NTA-agarose (QIAGEN) before washing, and stepwise removal of urea was performed to allow renaturation of bound protein. Proteins were eluted from Ni-agarose by 200 mM imidazole and were desalted on a PD-10 column (GE Healthcare) with Hanks\' balanced salt solution (Invitrogen).

TIRFM
-----

The Olympus total internal reflection system was used with a high-aperture objective lens (Apo 100× OHR; NA 1.65; Olympus) as previously published ([@bib22]). To observe GFP or Alexa Fluor 488 alone, we used a 488-nm laser line for excitation and a 515-nm long-pass filter for the barrier. Diiodomethane sulfur immersion oil (*n* = 1.81; Cargille Laboratories) was used to make contact between the objective lens and the high refractive index cover glass. Light propagates through the cover glass at an angle measured as 65° and undergoes total internal reflection at the glass--cell interface. The refractive indices for glass (*n* = 1.8 at 488 nm) and cells (*n* = 1.37) predict an evanescent field declining e-fold within 44 nm from the interface and to ∼10% within 100 nm. A granule 100 nm from the interface would be illuminated too dimly to be visible under our conditions. Thus, we look barely 100 nm into the cell, a distance comparable to the thickness of ultrathin sections cut for EM ([@bib42]). In an evanescent field declining e-fold within 44 nm, a granule at 80% brightness would have a vertical distance of 9.6 nm from the plasma membrane and qualify as a morphologically docked granule (granule distance from plasma membrane \<10 nm in EM studies; [@bib31]). Images were projected onto a CCD camera (DV887DCSBV; Andor) operated with MetaMorph version 6.3. Images were acquired at 300-ms intervals. For real-time images of GFP-tagged insulin granule motion by TIRFM, treated β cells were placed on the high refractive index glass, mounted in an open chamber, and incubated for 30 min at 37°C in KRB containing 110 mM NaCl, 4.4 mM KCl, 1.45 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 2.3 mM calcium gluconate, 4.8 mM NaHCO~3~, 2.2 mM glucose, 10 mM Hepes, pH 7.4, and 0.3% bovine serum albumin. Cells were then transferred to the thermostat-controlled stage (37°C) of TIRFM, and stimulation with glucose was achieved by the addition of 52 mM glucose-KRB into the chamber for a final concentration of 22 mM glucose. Most analyses, including tracking (single projection of different images) and area calculations were performed using MetaMorph software. To analyze the data, fusion events were manually selected, and the mean fluorescence intensity of individual granules in a 1 μm × 1 μm square placed over the granule center was calculated. The number of fusion events was manually counted while looping ∼5,000 frame time lapses. To observe the fluorescence of GFP and Cy3 simultaneously, we used the 488-nm laser line for excitation and an image splitter (Optical Insight) that divided the green and red components of the images with a 565-nm dichroic mirror (Q565; Chroma Technology Corp.), passing the green component through a 530 ± 15 nm bandpass filter (HQ530/30 m; Chroma Technology Corp.) and the red component through a 630 nm ± 25 nm bandpass filter (HQ630/50 m \[Chroma Technology Corp.\]; [@bib26]). Images were then projected side by side onto a CCD camera. The two images were brought into focus in the same plane by adding weak lenses to one channel, and they were brought into register by careful adjustment of the mirrors in the image splitter. Before each experimental session, we took an alignment image that showed density by means of scattered 90 nm TetraSpeck fluorescent beads (Invitrogen). They were visible in both the green and red channels, and thus provided markers in the x-y plane. Beads in the two images were brought into superposition by shifting one image using MetaMorph software.

Insulin release assay
---------------------

β cells were housed in a small chamber (∼5 × 10^5^ cells/chamber) and perfused with KRB (2.2 mM glucose) for 60 min at a flow rate of 0.5 ml/min at 37°C before collecting fractions. Insulin release was stimulated by 22 mM glucose. Fractions were collected at 1-min intervals. Insulin release in aliquots of media was measured by an insulin ELISA kit (Morinaga).

Measurement of \[Ca^2+^\]~i~
----------------------------

β cells were loaded with 2 μM fura-2 acetoxymethyl ester (Fura-2 AM; Invitrogen) for 30 min at 37°C in KRB (2.2 mM glucose) and washed and incubated for an additional 15 min with KRB. Coverslips were mounted on an ARGUS/HiSCA system (Hamamatsu Photonics). Fura-2 fluorescence was detected by the cooled CCD camera after excitation at 340 nm (F340) and 380 nm (F380), and the ratio image (F340/F380) was calculated with the ARGUS/HiSCA system.

Oral glucose tolerance test
---------------------------

Male mice age 10--14 wk were fasted for 14--15 h before the test. Glucose was administered orally at 2 g glucose/kg body weight. Blood samples were collected from a tail vein at 0, 30, 60, 90, and 120 min after loading. Blood glucose levels were measured by Glutest R (Sanwa Kagaku Kenkyusyo). Plasma insulin levels were measured by an insulin ELISA kit.

Online supplemental material
----------------------------

Fig. S1 shows a TIRF image of Synt1A clusters in the plasma membrane labeled with TAT-conjugated Cy3-labeled anti-Synt1A mAb and stained with anti-Synt1A pAb. Fig. S2 shows an immunoblot analysis of Synt1A and other SNARE proteins in the brain and pancreatic islets from WT and Synt1A^−/−^ mice. Fig. S3 shows microscopic examination of pancreatic islets in WT and Synt1A^−/−^ mice. Video 1 displays dual-color TIRF images of GFP-tagged insulin granules and Cy3-labeled Synt1A clusters during first-phase insulin release (0--4 min after glucose stimulation). Video 2 shows dual-color TIRFM of GFP-tagged insulin granules and Cy3-labeled Synt1A clusters during second-phase insulin release (\>4 min after glucose stimulation). Video 3 shows TIRFM of GFP-tagged insulin granule motion in the WT mouse β cell under 22 mM glucose stimulation. Video 4 shows TIRFM of GFP-tagged insulin granule motion in the Synt1A^−/−^ mouse β cell under 22 mM glucose stimulation. Video 5 shows TIRFM of GFP-tagged insulin granule motion in the Synt1A^−/−^ mouse β cell infected with Ax-Synt1A under 22 mM glucose stimulation. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200608132/DC1>.
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